Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Gulnaz Siddiqui¹  Heidi Maloni²  Victor E. Nava³ 

[1] Department of Biomedical Sciences and Department of Pathology, University of Missouri, Kansas City, MO, USA;Department of Neurology, Department of Veterans Affairs Medical Center, Washington, DC, USA;Department of Pathology, Department of Veterans Affairs Medical Center, Washington, DC, USA;

关键词: COVID-19;    Multiple sclerosis;    Anti-COVID-19 vaccination;    Sphingosine 1-phosphate receptor;    Modulators;    Disease-modifying therapy;   

DOI  :  10.1186/s41983-021-00428-8

来源: Springer

【 授权许可】

CC BY